RTI-112
This article may require cleanup to meet Wikipedia's quality standards. (Consider using more specific cleanup instructions.) Please help improve this article if you can. The talk page may contain suggestions. (August 2009) |
This article contains too much jargon and may need simplification or further explanation. Please discuss this issue on the talk page, and/or remove or explain jargon terms used in the article. Editing help is available. (August 2009) |
File:RTIoneonetwo.png | |
Systematic (IUPAC) name | |
---|---|
(1R,2S,3S)-methyl 3-(4-chloro-3-methylphenyl)-8-methyl-8-azabicyclo[3.2.1]octane-2-carboxylate | |
Identifiers | |
PubChem | CID 9904673 |
Chemical data | |
Formula | C17H22ClNO2 |
Molar mass | 307.82 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
RTI-112 (2β-carbomethoxy-3β-(3-methyl-4-chlorophenyl)tropane) is a synthetic stimulant drug from the phenyltropane family. In contrast to RTI-113 which is DAT selective, RTI-112 is a nonselective triple reuptake inhibitor.[1]
The in vitro tests actually show a very similar DAT/SERT/NET selectivity to cocaine,[2] although in vivo they behave differently.
"the nonselective monoamine transporter inhibitor RTI-126 and the DAT-selective inhibitors RTI-150 and RTI-336 both had a faster rate of onset (30 min) and a short duration of action (4h). In contrast, the nonselective monoamine transporter inhibitor RTI-112 had a slower rate of onset (30–60 min) and a longer duration of action (10h). The DAT-selective inhibitors RTI-171 and RTI-177 also had slower rates of onset (30–120 min), but RTI-171 had a short duration of action (2.5 h) while RTI-177 had a very long duration of action (20 h)."[3]
The efficacy of cocaine analogs to elicit self administration is related to the rate at which they are administered.
Slower onset analogs are less likely to function as behavioral stimulants than analogs sporting a faster rate of onset.[4]
Nonselective analogs are less likely to function as "reinforcers" than reuptake inhibitors that have DAT specificity.[3]
In order for a DRI such as cocaine to induce euphoria PET scans on primates reveal that the DAT occupancy needs to be >60%.[5]
RTI-112 is a particularly interesting nonselective cocaine-analog that has equipotent in vitro affinity at the SERT, NET and DAT, respectively.[2]
RTI-112 was not reliably self-administered, in contrast to the DAT selective reuptake inhibitors that were used in this study.[2]
Particularly notable is the fact that in vivo at the ED50, RTI-112 had no DAT occupancy at all.[2]
At the ED50, (mostly) all of the RTI-112 occupied the SERT at this dose.[2]
Significantly higher dose was required to get >70% DAT occupancy in the case of RTI-112.[2]
However RTI-112 was still able to suppress cocaine administration at the ED50 suggesting a serotonergic mechanism was responsible for this.[2]
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
- ↑ [1] Ginsburg, B.C., Kimmel, H.L., Carroll, F.I., Goodman, M.M., Howell, L.L. Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacology Biochemistry and Behavior, 80: 481-491, 2005.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 2.6 [2] Lindsey, K.P., Wilcox, K.M., Votaw, J.R., Goodman, M.M., Plisson, C., Carroll, F.I., Rice, K.C., Howell, L.L. Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. Journal of Pharmacology and Experimental Therapeutics, 309: 959-969, 2004.
- ↑ 3.0 3.1 Kimmel HL, O'Connor JA, Carroll FI, Howell LL. Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav. 2007 Jan;86(1):45-54. pmid 17258302
- ↑ [3] Wee S, Carroll FI, Woolverton WL. A Reduced Rate of In Vivo Dopamine Transporter Binding is Associated with Lower Relative Reinforcing Efficacy of Stimulants. Neuropsychopharmacology. 2006 Feb;31(2):351-62.
- ↑ [4] Howell, L.L. and Wilcox, K.M. The dopamine transporter and cocaine medication development: Drug self-administration in nonhuman primates. Journal of Pharmacology and Experimental Therapeutics, 298: 1-6, 2001.
- Pages with script errors
- Pages using duplicate arguments in template calls
- Articles needing cleanup from August 2009
- Articles with invalid date parameter in template
- All articles needing cleanup
- All pages needing cleanup
- Wikipedia articles needing style editing from August 2009
- All articles needing style editing
- Pages with broken file links
- Infobox drug tracked parameters
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugboxes with an unspecified ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Cocaine
- Dopamine reuptake inhibitors
- Stimulants
- Tropanes
- 2Fix
- Organochlorides